Evidence map›Paper›PMID 35452594›Full record

ArticleStem cell reports2022

Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan.

Taichi Hatta, Kazuki Ide, Misao Fujita, Tsunakuni Ikka

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Taichi HattaShizuoka Graduate University of Public Health, Aoi-ku, Shizuoka 420-0881, Japan.
Kazuki IdeDivision of Scientific Information and Public Policy, Center for Infectious Disease Education and Research, Osaka University, Suita, Osaka 565-0871, Japan; Research Center on Ethical, Legal and Social Issues, Osaka University, Suita, Osaka 565-0871, Japan.
Misao FujitaUehiro Research Division for iPS Cell Ethics, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), KUIAS Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: misao-fujita@cira.kyoto-u.ac.jp.
Tsunakuni IkkaNational Cancer Center Japan, Institute for Cancer Control, Division of Bioethics & Healthcare Law, Chuo-ku, Tokyo 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Master et al. (2021) declared that the unproven stem cell intervention (SCI) industry is a global health problem. We fully agree with this opinion but would like to point out that there are financial risks. In this letter, we estimate the total refund amount paid by the government for cell-based interventions offered under private practice in Japan.

Indexed as

Stem CellsJapan

Identifiers

PMID35452594
PMCPMC9133642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.